🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

20 results for “Structure” Clear

  1. The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study

    GlaxoSmithKline Biologicals S.A.

    Asthma with type 2 inflammation characterized by an eosinophilic phenotype

    phase 3 other active

    1 trial

  2. Aleniglipron

    Structure Therapeutics

    Obese

    phase 2 small molecule active

    1 trial

  3. Aleniglipron or Placebo

    Structure Therapeutics

    Obesity, Overweight, or Chronic Weight Management

    phase 2 small molecule active

    2 trials

  4. Anterior lamellar nanostructured artificial human cornea.

    Lxo Ireland Designated Activity Company

    Severe Trophic Corneal Ulcers Refractory to Conventional Treatment

    phase 2 small molecule completed

    1 trial

  5. GPC-100

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  6. GSBR-1290

    Structure Therapeutics

    Overweight or Obesity

    phase 2 small molecule completed

    1 trial

  7. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  8. TG-0054

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  9. TG-0054 (2.24 mg/kg)

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  10. TG-0054 combined with G-CSF

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  11. aleniglipron or placebo

    Structure Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  12. implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).

    Lxo Ireland Designated Activity Company

    Cleft Lip and Palate

    phase 2 other active

    1 trial

  13. A phase 1 study to assess the mass balance, pharmacokinetics, metabolism, and excretion of GSBR-1290, containing a microtracer dose of [14C] GSBR-1290, in healthy participants

    Structure Therapeutics

    Not applicable - Healthy volonteers

    phase 1 other active

    1 trial

  14. Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months

    United Therapeutics Europe Ltd

    Head and Neck Fibrosis

    phase 1 other completed

    1 trial

  15. GSBR-1290

    Structure Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  16. GSBR-1290 (Capsule/Tablet)

    Structure Therapeutics

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  17. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen Technology (Ireland) UC

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  18. TG-0054

    Structure Therapeutics

    Healthy

    phase 1 small molecule completed

    1 trial

  19. carotid-femoral pulse-wave velocity

    Structure Therapeutics

    Covid19

    other active

    1 trial

  20. substructure informed planning

    United Therapeutics Europe Ltd

    Brain Tumor

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources